Access to Medicine Foundation

From WikiCorporates
Jump to navigation Jump to search

The Access to Medicine Foundation is an independent non-profit organisation based in the Netherlands. Our mission is to stimulate and guide pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

We talk to experts about the actions pharmaceutical companies can and should be taking and then analyse what they are actually doing. In practice, that means analysing pharma companies’ actions and policies regarding access to medicine using a rigorous scoring and evaluation process. We benchmark companies against each other, and identify best practices and progress gaps. We make all of our results public and use our findings in our own outreach work to expand good practice across the industry.

Access to Medicine Index

The AtMI ranks 20 of the world’s largest pharmaceutical companies based on seven areas of behaviour linked to access: strategy, governance, R&D, pricing, licensing, capacity building and donations. By publicly recognising the best performers, the Index spurs companies to compete to be the best.


Antimicrobial Resistance Benchmark

Antibiotics are losing their effectiveness at an increasing rate, accelerated mostly by their misuse in humans, animals and crops. The drugs must be used sparingly, in order to minimise the chances for bacteria to outsmart them. There is now wide recognition at the highest political levels that more needs to be done urgently to slow the pace of antimicrobial resistance (AMR), with AMR initiatives being launched by the United Nations, the G7 and G20.

The Benchmark compares how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. It measures the 30 most active players in antimicrobial development and production and includes multinational pharmaceutical companies, biotechnology firms and manufacturers of generic medicines. ref

The ARB is the first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting where good ideas are being implemented, it will encourage their wide uptake. The 2018 Report looks at the following companies, and produces a Report Card for each: Achaogen Inc, Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd, Cempra Inc, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Entasis Therapeutics Inc, Fresenius Kabi AG, GlaxoSmithKline plc, Johnson & Johnson, Lupin Ltd, Macleods Pharmaceuticals Ltd, Melinta Therapeutics Inc, Merck & Co. Inc, MGB Biopharma, Motif Bio plc, Mylan NV, Nabriva Therapeutics plc, Novartis AG, Pfizer Inc, Polyphor Ltd, Roche Holding AG, Sanofi, Shionogi & Company Ltd, Summit Therapeutics plc, Sun Pharmaceutical Industries Ltd, Tetraphase Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, The Medicines Company, Wockhardt Ltd.

Funded by UK AID and the Dutch Ministry of Health, Welfare and Sport. ref, p.2

Access to Vaccines Index

The AtVI charts what vaccine companies are doing to ensure all children can be immunised, wherever they live. By uncovering what is working and where, the Index helps ensure vaccine markets also reach the poorest and most remote communities.


Funding

The Access to Medicine Foundation is an independent, non-profit organisation. We are funded exclusively by sources such as foundations, governments and development organisations. We do not receive funding from pharmaceutical companies or industry bodies. The Access to Medicine Foundation is funded by the UK Government, the Bill & Melinda Gates Foundation and the Dutch Ministry of Foreign Affairs. Its Access to Vaccines Index is funded by the Dutch Postcode Lottery. The Access to Medicine Foundation has registered charity status in the Netherlands (known as ANBI-status).